Timothy Kellett
Papers
1
Total Citations
7
H-Index
1
About
Dr. Timothy Kellett is a leading figure in cancer pharmacology, whose work has reshaped our understanding of DNA repair mechanisms and therapeutic resistance. His primary research focuses on the discovery and development of novel inhibitors targeting the PARP family of enzymes, with a particular emphasis on overcoming the limitations of current PARP inhibitors (PARPi) in BRCA-deficient and resistant cancers. Dr. Kellett’s most impactful contribution is his pioneering work on the Histone PARylation Factor 1 (HPF1), a critical co-factor that modulates PARP1 activity. In his highly cited 2023 study, he led the first high-throughput screening (HTS) campaign to identify small-molecule inhibitors of the PARP1-HPF1 complex. This breakthrough directly addresses a major clinical challenge: the narrow applicability of existing PARPi beyond BRCA-mutant tumors and the emergence of drug resistance. By targeting the complex rather than PARP1 alone, his work opens a new therapeutic avenue for a broader range of cancers. With his 2023 paper already garnering significant early citations, Dr. Kellett is recognized as a rising innovator in targeted cancer therapy, bridging fundamental biochemistry with translational drug discovery.
Research Focus
Key Achievements
Top Papers
- 1HTS discovery of PARP1-HPF1 complex inhibitors in cancer7 citations · 2023